BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Youngblood BA, Brock EC, Leung J, Falahati R, Bochner BS, Rasmussen HS, Peterson K, Bebbington C, Tomasevic N. Siglec-8 antibody reduces eosinophils and mast cells in a transgenic mouse model of eosinophilic gastroenteritis. JCI Insight 2019;4:126219. [PMID: 31465299 DOI: 10.1172/jci.insight.126219] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 12.3] [Reference Citation Analysis]
Number Citing Articles
1 Fernandez A, Asbell P, Roy N. Emerging therapies targeting eosinophil-mediated inflammation in chronic allergic conjunctivitis. Ocul Surf 2022:S1542-0124(22)00076-3. [PMID: 35970432 DOI: 10.1016/j.jtos.2022.08.004] [Reference Citation Analysis]
2 Pitlick MM, Li JT, Pongdee T. Current and emerging biologic therapies targeting eosinophilic disorders. World Allergy Organization Journal 2022;15:100676. [DOI: 10.1016/j.waojou.2022.100676] [Reference Citation Analysis]
3 Bochner BS, O'Sullivan JA, Chang AT, Youngblood BA. Siglecs in allergy and asthma. Mol Aspects Med 2022;:101104. [PMID: 35835621 DOI: 10.1016/j.mam.2022.101104] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Xu L, Tian D, Zhou M, Ma J, Sun G, Jin H, Li M, Zhang D, Wu J. OX40 Expression in Eosinophils Aggravates OVA-Induced Eosinophilic Gastroenteritis. Front Immunol 2022;13:841141. [PMID: 35720294 DOI: 10.3389/fimmu.2022.841141] [Reference Citation Analysis]
5 Dhar A, Haboubi HN, Attwood SE, Auth MKH, Dunn JM, Sweis R, Morris D, Epstein J, Novelli MR, Hunter H, Cordell A, Hall S, Hayat JO, Kapur K, Moore AR, Read C, Sami SS, Turner PJ, Trudgill NJ. British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophilic oesophagitis in children and adults. Gut 2022:gutjnl-2022-327326. [PMID: 35606089 DOI: 10.1136/gutjnl-2022-327326] [Reference Citation Analysis]
6 Sher ER, Ross JA, Weine DM, Chandini Arjun A. Current and emerging therapies for eosinophilic esophagitis. Allergy Asthma Proc 2022;43:178-86. [PMID: 35524356 DOI: 10.2500/aap.2022.43.220014] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 McCord KA, Macauley MS. Transgenic mouse models to study the physiological and pathophysiological roles of human Siglecs. Biochem Soc Trans 2022:BST20211203. [PMID: 35383825 DOI: 10.1042/BST20211203] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 Marabotto E, Giannini EG, Zentilin P, Ziola S, Djahandideh Sheijani A, Savarino E, Savarino V. Pharmacotherapies in eosinophilic esophagitis: state of the art. Minerva Gastroenterol (Torino) 2022;68:69-76. [PMID: 35302339 DOI: 10.23736/S2724-5985.21.02781-1] [Reference Citation Analysis]
9 Puzzovio PG, Brüggemann TR, Pahima H, Mankuta D, Levy BD, Levi-Schaffer F. Cromolyn Sodium differentially regulates human mast cell and mouse leukocyte responses to control allergic inflammation. Pharmacol Res 2022;:106172. [PMID: 35278626 DOI: 10.1016/j.phrs.2022.106172] [Reference Citation Analysis]
10 Lam AY, Ma C, Lee JK, Bredenoord AJ. Eosinophilic esophagitis: New molecules, better life? Curr Opin Pharmacol 2022;63:102183. [PMID: 35176546 DOI: 10.1016/j.coph.2022.102183] [Reference Citation Analysis]
11 Korver W, Wong A, Gebremeskel S, Negri GL, Schanin J, Chang K, Leung J, Benet Z, Luu T, Brock EC, Luehrsen K, Xu A, Youngblood BA. The Inhibitory Receptor Siglec-8 Interacts With FcεRI and Globally Inhibits Intracellular Signaling in Primary Mast Cells Upon Activation. Front Immunol 2022;13:833728. [DOI: 10.3389/fimmu.2022.833728] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
12 Racca F, Pellegatta G, Cataldo G, Vespa E, Carlani E, Pelaia C, Paoletti G, Messina MR, Nappi E, Canonica GW, Repici A, Heffler E. Type 2 Inflammation in Eosinophilic Esophagitis: From Pathophysiology to Therapeutic Targets. Front Physiol 2022;12:815842. [DOI: 10.3389/fphys.2021.815842] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Kuźmiński A, Przybyszewski M, Przybyszewska J, Bartuzi Z. Eosinophilic esophagitis. What diet? How to treat it? The point of view of a gastroenterologist working in a department of allergology. Prz Gastroenterol 2021;16:318-23. [PMID: 34976239 DOI: 10.5114/pg.2021.105163] [Reference Citation Analysis]
14 Cao X, Cordova AF, Li L. Therapeutic Interventions Targeting Innate Immune Receptors: A Balancing Act. Chem Rev 2021. [PMID: 34870969 DOI: 10.1021/acs.chemrev.1c00716] [Reference Citation Analysis]
15 Dunn JLM, Rothenberg ME. 2021 year in review: Spotlight on eosinophils. J Allergy Clin Immunol 2021:S0091-6749(21)01796-6. [PMID: 34838883 DOI: 10.1016/j.jaci.2021.11.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Choi HW, Naskar M, Seo HK, Lee HW. Tumor-Associated Mast Cells in Urothelial Bladder Cancer: Optimizing Immuno-Oncology. Biomedicines 2021;9:1500. [PMID: 34829729 DOI: 10.3390/biomedicines9111500] [Reference Citation Analysis]
17 Camilleri AE, Nag S, Russo AR, Stiles KM, Crystal RG, Pagovich OE. Gene therapy for a murine model of eosinophilic esophagitis. Allergy 2021;76:2740-52. [PMID: 33748982 DOI: 10.1111/all.14822] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Peterson K, Safroneeva E, Schoepfer A. Emerging Therapies for Eosinophilic Gastrointestinal Diseases. J Allergy Clin Immunol Pract 2021;9:3276-81. [PMID: 34343695 DOI: 10.1016/j.jaip.2021.07.031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
19 Rodrigo-Muñoz JM, Gil-Martínez M, Sastre B, Del Pozo V. Emerging Evidence for Pleiotropism of Eosinophils. Int J Mol Sci 2021;22:7075. [PMID: 34209213 DOI: 10.3390/ijms22137075] [Reference Citation Analysis]
20 Dellon ES, Gonsalves N, Rothenberg ME, Hirano I, Chehade M, Peterson KA, Falk GW, Murray JA, Gehman LT, Chang AT, Singh B, Rasmussen HS, Genta RM. Determination of Biopsy Yield That Optimally Detects Eosinophilic Gastritis and/or Duodenitis in a Randomized Trial of Lirentelimab. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00592-9. [PMID: 34089846 DOI: 10.1016/j.cgh.2021.05.053] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
21 Fiocchi A, Vickery BP, Wood RA. The use of biologics in food allergy. Clin Exp Allergy 2021;51:1006-18. [PMID: 33966304 DOI: 10.1111/cea.13897] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Lichterman JN, Reddy SM. Mast Cells: A New Frontier for Cancer Immunotherapy. Cells 2021;10:1270. [PMID: 34063789 DOI: 10.3390/cells10061270] [Reference Citation Analysis]
23 Delaveris CS, Chiu SH, Riley NM, Bertozzi CR. Modulation of immune cell reactivity with cis-binding Siglec agonists. Proc Natl Acad Sci U S A 2021;118:e2012408118. [PMID: 33431669 DOI: 10.1073/pnas.2012408118] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
24 Delaveris CS, Wilk AJ, Riley NM, Stark JC, Yang SS, Rogers AJ, Ranganath T, Nadeau KC, Blish CA, Bertozzi CR; Stanford COVID-19 Biobank. Synthetic Siglec-9 Agonists Inhibit Neutrophil Activation Associated with COVID-19. ACS Cent Sci 2021;7:650-7. [PMID: 34056095 DOI: 10.1021/acscentsci.0c01669] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
25 Sturm EM, Knuplez E, Marsche G. Role of Short Chain Fatty Acids and Apolipoproteins in the Regulation of Eosinophilia-Associated Diseases. Int J Mol Sci 2021;22:4377. [PMID: 33922158 DOI: 10.3390/ijms22094377] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Lucendo AJ, López-Sánchez P. Targeted Therapies for Eosinophilic Gastrointestinal Disorders. BioDrugs 2020;34:477-93. [PMID: 32472465 DOI: 10.1007/s40259-020-00427-w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
27 Gotlib J, George TI, Carter MC, Austen KF, Bochner B, Dwyer DF, Lyons JJ, Hamilton MJ, Butterfield J, Bonadonna P, Weiler C, Galli SJ, Schwartz LB, Elberink HO, Maitland A, Theoharides T, Ustun C, Horny HP, Orfao A, Deininger M, Radia D, Jawhar M, Kluin-Nelemans H, Metcalfe DD, Arock M, Sperr WR, Valent P, Castells M, Akin C. Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference. J Allergy Clin Immunol 2021;147:2043-52. [PMID: 33745886 DOI: 10.1016/j.jaci.2021.03.008] [Reference Citation Analysis]
28 Gebremeskel S, Schanin J, Coyle KM, Butuci M, Luu T, Brock EC, Xu A, Wong A, Leung J, Korver W, Morin RD, Schleimer RP, Bochner BS, Youngblood BA. Mast Cell and Eosinophil Activation Are Associated With COVID-19 and TLR-Mediated Viral Inflammation: Implications for an Anti-Siglec-8 Antibody. Front Immunol 2021;12:650331. [PMID: 33777047 DOI: 10.3389/fimmu.2021.650331] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
29 Schneider AL, Schleimer RP, Tan BK. Targetable pathogenic mechanisms in nasal polyposis. Int Forum Allergy Rhinol 2021;11:1220-34. [PMID: 33660425 DOI: 10.1002/alr.22787] [Reference Citation Analysis]
30 Jacobsen EA, Jackson DJ, Heffler E, Mathur SK, Bredenoord AJ, Pavord ID, Akuthota P, Roufosse F, Rothenberg ME. Eosinophil Knockout Humans: Uncovering the Role of Eosinophils Through Eosinophil-Directed Biological Therapies. Annu Rev Immunol 2021;39:719-57. [PMID: 33646859 DOI: 10.1146/annurev-immunol-093019-125918] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
31 Youngblood BA, Leung J, Falahati R, Williams J, Schanin J, Brock EC, Singh B, Chang AT, O'Sullivan JA, Schleimer RP, Tomasevic N, Bebbington CR, Bochner BS. Discovery, Function, and Therapeutic Targeting of Siglec-8. Cells 2020;10:E19. [PMID: 33374255 DOI: 10.3390/cells10010019] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
32 Delaveris CS, Wilk AJ, Riley NM, Stark JC, Yang SS, Rogers AJ, Ranganath T, Nadeau KC, Blish CA, Bertozzi CR; Stanford COVID-19 Biobank. Synthetic Siglec-9 Agonists Inhibit Neutrophil Activation Associated with COVID-19. ChemRxiv 2020. [PMID: 33469569 DOI: 10.26434/chemrxiv.13378148] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Lenza MP, Atxabal U, Oyenarte I, Jiménez-Barbero J, Ereño-Orbea J. Current Status on Therapeutic Molecules Targeting Siglec Receptors. Cells 2020;9:E2691. [PMID: 33333862 DOI: 10.3390/cells9122691] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
34 Ghisa M, Laserra G, Maniero D, Marabotto E, Barberio B, Pelizzaro F, Barbuscio I, Zingone F, Savarino V, Savarino E. Eosinophilic esophagitis: from pathophysiology to management. Minerva Gastroenterol (Torino) 2022;68:40-8. [PMID: 33267562 DOI: 10.23736/S2724-5985.20.02780-4] [Reference Citation Analysis]
35 Dellon ES, Peterson KA, Murray JA, Falk GW, Gonsalves N, Chehade M, Genta RM, Leung J, Khoury P, Klion AD, Hazan S, Vaezi M, Bledsoe AC, Durrani SR, Wang C, Shaw C, Chang AT, Singh B, Kamboj AP, Rasmussen HS, Rothenberg ME, Hirano I. Anti-Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis. N Engl J Med 2020;383:1624-34. [PMID: 33085861 DOI: 10.1056/NEJMoa2012047] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 16.0] [Reference Citation Analysis]
36 Lyons JJ, Metcalfe DD. Targeting Mast Cells with Biologics. Immunology and Allergy Clinics of North America 2020;40:667-85. [DOI: 10.1016/j.iac.2020.06.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
37 Ford AC, Mahadeva S, Carbone MF, Lacy BE, Talley NJ. Functional dyspepsia. The Lancet 2020;396:1689-702. [DOI: 10.1016/s0140-6736(20)30469-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 10] [Article Influence: 14.5] [Reference Citation Analysis]
38 Syverson EP, Hait EJ. Treatment for eosinophilic esophagitis. Curr Opin Gastroenterol 2020;36:485-90. [PMID: 33009017 DOI: 10.1097/MOG.0000000000000681] [Reference Citation Analysis]
39 Valent P, Akin C, Hartmann K, Nilsson G, Reiter A, Hermine O, Sotlar K, Sperr WR, Escribano L, George TI, Kluin-Nelemans HC, Ustun C, Triggiani M, Brockow K, Gotlib J, Orfao A, Kovanen PT, Hadzijusufovic E, Sadovnik I, Horny HP, Arock M, Schwartz LB, Austen KF, Metcalfe DD, Galli SJ. Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts. Theranostics 2020;10:10743-68. [PMID: 32929378 DOI: 10.7150/thno.46719] [Cited by in Crossref: 45] [Cited by in F6Publishing: 29] [Article Influence: 22.5] [Reference Citation Analysis]
40 Reed CC, Genta RM, Youngblood BA, Wechsler JB, Dellon ES. Mast Cell and Eosinophil Counts in Gastric and Duodenal Biopsy Specimens From Patients With and Without Eosinophilic Gastroenteritis. Clin Gastroenterol Hepatol 2021;19:2102-11. [PMID: 32801015 DOI: 10.1016/j.cgh.2020.08.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
41 Doulberis M, Kountouras J, Rogler G. Reconsidering the "protective" hypothesis of Helicobacter pylori infection in eosinophilic esophagitis. Ann N Y Acad Sci 2020;1481:59-71. [PMID: 32770542 DOI: 10.1111/nyas.14449] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 Marzano AV, Genovese G. Eosinophilic Dermatoses: Recognition and Management. Am J Clin Dermatol 2020;21:525-39. [PMID: 32394361 DOI: 10.1007/s40257-020-00520-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 5.5] [Reference Citation Analysis]
43 Kerr SC, Gonzalez JR, Schanin J, Peters MC, Lambrecht BN, Brock EC, Charbit A, Ansel KM, Youngblood BA, Fahy JV. An anti-siglec-8 antibody depletes sputum eosinophils from asthmatic subjects and inhibits lung mast cells. Clin Exp Allergy 2020;50:904-14. [PMID: 32542913 DOI: 10.1111/cea.13681] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
44 Wielgat P, Rogowski K, Niemirowicz-Laskowska K, Car H. Sialic Acid-Siglec Axis as Molecular Checkpoints Targeting of Immune System: Smart Players in Pathology and Conventional Therapy. Int J Mol Sci 2020;21:E4361. [PMID: 32575400 DOI: 10.3390/ijms21124361] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
45 Vitallé J, Terrén I, Orrantia A, Bilbao A, Gamboa PM, Borrego F, Zenarruzabeitia O. The Expression and Function of CD300 Molecules in the Main Players of Allergic Responses: Mast Cells, Basophils and Eosinophils. Int J Mol Sci 2020;21:E3173. [PMID: 32365988 DOI: 10.3390/ijms21093173] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
46 Knuplez E, Krier-Burris R, Cao Y, Marsche G, O'Sullivan J, Bochner BS. Frontline Science: Superior mouse eosinophil depletion in vivo targeting transgenic Siglec-8 instead of endogenous Siglec-F: Mechanisms and pitfalls. J Leukoc Biol 2020;108:43-58. [PMID: 32134149 DOI: 10.1002/JLB.3HI0120-381R] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
47 O'Sullivan JA, Chang AT, Youngblood BA, Bochner BS. Eosinophil and mast cell Siglecs: From biology to drug target. J Leukoc Biol 2020;108:73-81. [PMID: 31965606 DOI: 10.1002/JLB.2MR0120-352RR] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 10.0] [Reference Citation Analysis]
48 Lucendo AJ. Pharmacological treatments for eosinophilic esophagitis: current options and emerging therapies. Expert Rev Clin Immunol 2020;16:63-77. [PMID: 31842634 DOI: 10.1080/1744666X.2019.1705784] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
49 Agache I, Cojanu C, Laculiceanu A, Rogozea L. Critical Points on the Use of Biologicals in Allergic Diseases and Asthma. Allergy Asthma Immunol Res 2020;12:24-41. [PMID: 31743962 DOI: 10.4168/aair.2020.12.1.24] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
50 Aceves S, Collins MH, Rothenberg ME, Furuta GT, Gonsalves N; Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). Advancing patient care through the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). J Allergy Clin Immunol 2020;145:28-37. [PMID: 31758958 DOI: 10.1016/j.jaci.2019.11.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
51 Greuter T, Hirano I, Dellon ES. Emerging therapies for eosinophilic esophagitis. J Allergy Clin Immunol 2020;145:38-45. [PMID: 31705907 DOI: 10.1016/j.jaci.2019.10.027] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
52 Pesek RD, Rothenberg ME. Eosinophilic gastrointestinal disease below the belt. J Allergy Clin Immunol 2020;145:87-89.e1. [PMID: 31669097 DOI: 10.1016/j.jaci.2019.10.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
53 Strattan E, Palaniyandi S, Kumari R, Du J, Hakim N, Huang T, Kesler MV, Jennings CD, Sturgill JL, Hildebrandt GC. Mast Cells Are Mediators of Fibrosis and Effector Cell Recruitment in Dermal Chronic Graft-vs.-Host Disease. Front Immunol 2019;10:2470. [PMID: 31681336 DOI: 10.3389/fimmu.2019.02470] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]